TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02287948

Intervention type: DEVICE
Intervention: Nintendo Wii Fit Balance Board
Description: Clinical and instrumental evaluations carry out on the same day.~1) Instrumental evaluations~All subjects (healthy + MS) will ask to perform the following tasks both on force platform and Wii Fit Balance Board:~* Open eyes, monopodalic balance for 20 seconds~* Closed eyes, monopodalic balance for 20 seconds~* Open eyes, balance on both feet for 60 seconds~* Closed eyes, balance on both feet for 60 seconds~During trials subjects can leave arms in the most comfortable position they prefere~Subjects will perform every task for 5 times; they can rest for 30 seconds between every trials.

Intervention type: DEVICE
Intervention: Nintendo Wii Fit Balance Board
Description: Clinical and instrumental evaluations carry out on the same day.~1) Instrumental evaluations~All subjects (healthy + MS) will ask to perform the following tasks both on force platform and Wii Fit Balance Board:~* Open eyes, monopodalic balance for 20 seconds~* Closed eyes, monopodalic balance for 20 seconds~* Open eyes, balance on both feet for 60 seconds~* Closed eyes, balance on both feet for 60 seconds~During trials subjects can leave arms in the most comfortable position they prefere~Subjects will perform every task for 5 times; they can rest for 30 seconds between every trials.
Study: NCT00911716

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study: NCT03256201

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional Counseling
Description: Patients in both arms receive a single counseling session with a licensed dietician to determine individual protein goal for body weight and current dietary intake. Goal is then met through protein supplementation (provided) if needed beyond dietary intake.
Study: NCT00911716

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Study: NCT03402399

Intervention type: OTHER
Group type: OTHER
Intervention: Molecular analysis
Description: Blood test

Intervention type: OTHER
Group type: OTHER
Intervention: Molecular analysis
Description: Blood test
Study: NCT03256201

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional Counseling
Description: Patients in both arms receive a single counseling session with a licensed dietician to determine individual protein goal for body weight and current dietary intake. Goal is then met through protein supplementation (provided) if needed beyond dietary intake.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Exercise
Description: Patients receive a single instruction session with a physical therapist, for training in moderate intensity (using Rate of Perceived Exertion) exercise including cardiovascular endurance, flexibility, and AROM of upper and lower body. If no other preferred mode of endurance training, a home ergometer is provided for use with arms and/or legs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Exercise
Description: Patients receive a single instruction session with a physical therapist, for training in moderate intensity (using Rate of Perceived Exertion) exercise including cardiovascular endurance, flexibility, and resistance exercise for upper and lower body. If no other preferred mode of endurance training, a home ergometer is provided for use with arms and/or legs.
Study: NCT04255589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-495 75mg
Description: CKD-495 75mg Tab.
Study: NCT02060305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab intra-articular injection
Description: Bevacizumab, 20\~40mg, intra-articular injection every 28 days for 4 times
Study: NCT02378129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer cement Clinpro XT
Description: Clinpro XT (3M ESPE, Minnesota, USA)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glass Ionomer cement Vidrion R
Description: Vidrion R (SS White, Gloucester, UK)
Study: NCT01665001

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment strategy: induction, consolidation, HSCT, maintenance
Description: Patients \<55 years Ph-neg.: induction (daunorubicin, prednisone, vincristin, PEG-asparaginase), 2nd induction (if non-remission or MRD\>0.1%; FLAM, MiniFLAM or FLAM-CAMP dependent on age and phenotype), consolidation (methotrexate, etoposide, cytarabine, cyclophosphamide, PEG-asparaginase). If MRD \<0.01%: autoHSCT + maintenance (mercaptopurine, methotrexate) or multiagent maintenance (additionally daunorubicin, vincristin, prednisone); remaining patients: alloHSCT. Prophylaxis of leptomeningeal involvement: liposomal cytarabine intrathecally.~Patients \>55 years, Ph-neg.: as above, reduced doses. AlloHSCT with reduced conditioning.~Patients Ph-pos.: as above, reduced doses in combination with continues imatinib. All intended for alloHSCT.
Study: NCT01926405

Intervention type: PROCEDURE
Group type: OTHER
Intervention: saliva collection
Description: collection of saliva

Intervention type: PROCEDURE
Group type: OTHER
Intervention: saliva collection
Description: collection of saliva
Study: NCT00276484

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin
Description: Atorvastatin 80 mg tablet by mouth, once a day for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: Atorvastatin 40 mg by mouth, once a day for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezetimibe
Description: Ezetimibe 10 mg tablets by mouth, once a day for 6 weeks.
Study: NCT04184427

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Anterior Power Arm
Description: Crimpable stainless steel hook placed on orthodontic base arch wire.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anterior Power Arm
Description: Crimpable stainless steel hook placed on orthodontic base arch wire.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anterior Power Arm
Description: Crimpable stainless steel hook placed on orthodontic base arch wire.
Study: NCT02577991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decadron
Description: 10 mg of intraoperative intravenous decadron with gel foam sponge placed on cervical plate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone
Description: 40 mg of triamcinolone on gel foam sponge dabbed on the anterior cervical plate
Study: NCT01796600

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The patients will have a conventional scanner, a reference examination, and a cone-beam scanner Newtom 5G just after the conventional scanner
Study: NCT03447639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-iodine irrigation
Description: Single dose, 60 cc of 2% povidone-iodine indwelling for 10 minutes prior to catheter removal using aseptic technique
Study: NCT01384110

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Reduction of glycemic index of ingested foods
Description: Oral administration of the experimental lemon tea powder(56.1 g) and the placebo lemon tea powder (55.6 g) dissolved in water. Each participant will receive both treatment in a cross-over protocol design during 2 visits separated by a 2-weeks period. The day before both intervention, participants will consume a standardised meal for the supper.
Study: NCT02017509

Intervention type: PROCEDURE
Intervention: Diagnostic Biopsy and Surgical Procedure
Description: A tumor sample from the diagnostic biopsy and surgical procedure will be used for research.

Intervention type: PROCEDURE
Intervention: Intravoxel incoherent motion MRI (IVIM)
Description: At the end of a standard MRI, we will perform IVIM, which is a diffusion-weighted imaging sequence that simultaneously characterizes the microscopic diffusivity of water and the macroscopic transport of water via bulk flow. IVIM may more accurately reflect the properties of the tumor microenvironment including vascular permeability, interstitial fluid pressure, and response to neoadjuvant therapy.
Study: NCT04271111

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Treatment for Interpersonal Stress
Description: Intervention designed to build social support and reduce loneliness by giving participants skills to strengthen their relationships

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Health Education Tool
Description: Intervention designed to improve physical health through exercise, eating habits, and sleep
Study: NCT01384110

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Reduction of glycemic index of ingested foods
Description: Oral administration of the experimental lemon tea powder(56.1 g) and the placebo lemon tea powder (55.6 g) dissolved in water. Each participant will receive both treatment in a cross-over protocol design during 2 visits separated by a 2-weeks period. The day before both intervention, participants will consume a standardised meal for the supper.
Study: NCT04166201

Intervention type: PROCEDURE
Group type: OTHER
Intervention: double mesh hernioplasty with modified chevrel's technique
Description: hernioplasty done by modification of the chevrel's technique , no dissection further than 1 cm of the midline laterally, the medial flaps of the anterior rectus sheath is dissected of the anterior surface of the rectus abdominis muscle and sutured together reforming the posterior rectus sheath , one polypropylene mesh was fixed over the posterior rectus sheath and the other was tailored to raw area of the rectis abdominis muscle and sutured to the lateral free edges of the anterior rectus sheath
Study: NCT02938143

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The intervention treatment is a progressive 4-stage criteria-based exercise protocol within the limits of pain, consisting of progressive isometric, isotonic, plyometric, and sport-specific exercises.24 Progression criteria are individualized.
Study: NCT00002524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim-Sulfamethoxazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidovudine (AZT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidovudine (AZT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidovudine (AZT)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Study: NCT01397175

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biolimus-eluting stent
Description: Biolimus-eluting stent (BES, BioMatrix or BioMatrix Flex, Biosensors, USA) has bio-degradable polymer which is consisted with poly-lactic acid (PLA) and degraded into H2O and CO2 while releasing the biolimus. BES would be expected to reduce the stent thrombosis comparing with the DES with durable polymer.
Study: NCT02017509

Intervention type: PROCEDURE
Intervention: Dynamic Contrast Enhanced MRI (DCE-MRI)
Description: Following a standard MRI scan, Dynamic Contrast Enhanced MRI (DCE-MRI) will be done. DCE-MRI is an indicator-dilution experiment in which the delivery and transcapillary transfer of a contrast agent, typically one of a number of gadolinium-based contrast agents (GBCA), is used to assess a number of parameters characterizing tissue physiology. In locally advanced rectal cancer patients, use of DCE-MRI for determining pathologic response has produced equivocal results but more promising data has been published recently in the cervical cancer literature.

Intervention type: GENETIC
Intervention: RNA gene expression analysis
Description: RNA will be collected from biopsy and surgical tissue for gene expression analysis.
Study: NCT02837705

Intervention type: OTHER
Intervention: blood draw

Intervention type: OTHER
Intervention: blood draw
Study: NCT02575014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preoperative hyperbaric oxygen
Description: Subjects undergoing preoperative HBOT will be treated with up to 2.4 ATA O2, for a maximum of 90 minutes each day with or without air breaks, as deemed necessary by the investigator, for two days. The two days will be the day of and the day immediately prior to the operation.
Study: NCT01397175

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus-eluting stent
Description: Everolimus-eluting stent (EES, Xience V or Xience Prime, Abbott, USA) use the MULTILINK VISION stent platform and durable polymer containing everolimus. It has the thinnest strut thickness among the available DES in Korea.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zotarolimus-eluting stent
Description: Zotarolimus-eluting stent with biolinx polymer (ZES, Endeavor Resolute or Endeavor Resolute Intergrity, Medtronic, USA) has DRIVER stent platform. The durable polymer in this DES has changed from phosphorylcholine (PC) polymer which was used in Endeavor to Biolinx polymer which has more biocompatible features.
Study: NCT00963339

Intervention type: DEVICE
Intervention: Foresee Home
Description: Home Monitoring
Study: NCT03697018

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: zirconia reinforced lithium silicate glass ceramic
Description: It represent a new generation of glass ceramic material. Using an innovative manufacturing process the glass ceramic is enriched with zirconia (10% by weight) for dental CAD/CAM applications for the fabrication of inlays, onlays, crowns and anterior and posterior single tooth restorations on implant abutments.
Study: NCT02272413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 695502

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avastin
Study: NCT02150668

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Homework, Organization, and Planning Skills (HOPS) Intervention
Study: NCT03697018

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: zirconia reinforced lithium silicate glass ceramic
Description: It represent a new generation of glass ceramic material. Using an innovative manufacturing process the glass ceramic is enriched with zirconia (10% by weight) for dental CAD/CAM applications for the fabrication of inlays, onlays, crowns and anterior and posterior single tooth restorations on implant abutments.
Study: NCT02167191

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIT
Description: 12 sessions of HIT exercise in 31 days on a stationary cycle ergometer
Study: NCT02150668

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Homework Support Intervention (HSI)
Study: NCT03003975

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PVI by single cryoballoon application guided by Achieve Mapping Catheter
Description: Pulmonary vein isolation by single cryoballoon application guided by recorded electrogram signals from an internal Mapping Catheter and by temperature drop if mapping of signals is not possible (temperature cutoff \< or = -40 degrees C)
Study: NCT04255589

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg
Description: Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg Tab.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of the CKD-495 75mg
Description: Placebo of the CKD-495 75mg Tab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg
Description: Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab.
Study: NCT03003975

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PVI by 2 routine cryoballoon applications
Description: Pulmonary vein isolation by 2 cryoballoon applications guided by degree of occlusion and by temperature drop according to discretion of physician
Study: NCT03857087

Intervention type: DRUG
Intervention: Gallium Ga 68-labeled PSMA-11
Description: Given IV

Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging (MRI)
Description: Given PET/MRI

Intervention type: PROCEDURE
Intervention: Positron Emission Tomography (PET)
Description: Undergo PET/MRI
Study: NCT02802280

Intervention type: OTHER
Group type: OTHER
Intervention: Cardiovascular risk in HCV patients
Description: Cardiovascular risk assessement (through Flow-mediated vasodilatation FMV, measurement of endothelial function biomarkers, carotid ultrasound, etc.)~This is a prospective study. The only intervention planned will consist of performing different tests that define the individual cardiovascular risk. These tests will be carried out on a single group cohort at different times.~Notwithstanding, the investigators will record the exposure to DAA to assess any change in CVR.~Anti-HCV regimens will be used according to clinical practice as indicated into the current guidelines (1)~(1)European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015 Jul;63(1):199-236. doi: 10.1016/j.jhep.2015.03.025. Epub 2015 Apr 21. PubMed PMID: 25911336.
Study: NCT03580031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hCG
Description: A booster dose (10,000 IU of hCG) was given IM 48 hours after first triggering dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: 2 ml of normal saline will be injected 48 hours after first triggering dose
Study: NCT02331680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-41061
Study: NCT02531724

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levosimendan
Study: NCT02331680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-41061

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04158518

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Toxicities reduced treatment
Description: Drug: docetaxel and cisplatin (Induction chemotherapy) Patients receive docetaxel (75 mg/m2 d1) and cisplatin (25mg/m2 d1-3) every 3 weeks for 3 cycles before IMRT.~Omitting concurrent cisplatin chemotherapy when responses to induction chemotherapy are ≥ 50% Partial Response(PR).~Radiation: IMRT Intensity modulated-radiotherapy (IMRT) is given as 2.2 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 or 70.4 Gy to the primary tumor.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Drug: docetaxel and cisplatin (Induction chemotherapy) Patients receive docetaxel (75 mg/m2 d1) and cisplatin (25mg/m2 d1-3) every 3 weeks for 3 cycles before IMRT.~Concurrent cisplatin chemoradiotherapy delivered when responses to induction chemotherapy are less than 50% Partial Response(PR).~Radiation: IMRT Intensity modulated-radiotherapy (IMRT) is given as 2.2 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 or 70.4 Gy to the primary tumor.
Study: NCT00750061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate
Description: The subject start at a dosage regime of three times a day and one tablet of lithium carbonate, 250mg/table, oral administration each time for three days. The daily dose will be adjusted according to the serum lithium level and the clinical findings. Target serum lithium level is 0.6-1.2mM.~The course of medication is 6 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT02531724

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium chloride
Study: NCT03939975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab or nivolumab or JS001
Description: ICIs therapy of nivolumab (3 mg/kg, per 2 weeks) or pembrolizumab (2 mg/kg, per 3 weeks) or JS001 (240mg, per 3 weeks) was performed until the off-treatment criteria were met. For participants with stable disease or atypical progression to ICIs therapy, thermal ablation of radiofrequency ablation or microwave ablation was performed addtionally.
Study: NCT02661243

Intervention type: DEVICE
Group type: OTHER
Intervention: Biohorizons Laser-lok bonelevel dental implants
Description: Insertion of Biohorizons Laser-lok bonelevel dental implants to replace missing (pre)molars or to stabilize a denture

Intervention type: DEVICE
Group type: OTHER
Intervention: Biohorizons Laser-lok bonelevel dental implants
Description: Insertion of Biohorizons Laser-lok bonelevel dental implants to replace missing (pre)molars or to stabilize a denture

Intervention type: DEVICE
Group type: OTHER
Intervention: Biohorizons Laser-lok bonelevel dental implants
Description: Insertion of Biohorizons Laser-lok bonelevel dental implants to replace missing (pre)molars or to stabilize a denture

Intervention type: DEVICE
Group type: OTHER
Intervention: Biohorizons Laser-lok bonelevel dental implants
Description: Insertion of Biohorizons Laser-lok bonelevel dental implants to replace missing (pre)molars or to stabilize a denture
Study: NCT01895595

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Imagery

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Digital Storytelling
Study: NCT03055520

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive training
Description: The Kumon method (www.kumon.com) of arithmetic calculation employs the errorless-learning (EL) strategy and consists of a structured, hierarchical series of exercises, beginning with simple ones (e.g. addition and subtraction) and then proceeding to more complex exercises (e.g. advanced algebra, calculus).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: nonspecific recreation including befriending and free simple activities.
Study: NCT00907504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-751,871
Description: CP-751,871 20mg/kg every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 80 mg/m2 every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1,250 mg/m2 Day1+8 of evey 3 week-cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 80 mg/m2 every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine 1,250 mg/m2 Day1+8 of evey 3 week-cycle
Study: NCT02899091

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CB-AC-02
Description: Stage1:~① Group1: CB-AC-02 administration on day 0~② Group2: CB-AC-02 administration on day 0 and on week 4 (repeated injection)~Stage2~① Arm1: K-MMSE 20\~26 CB-AC-02 administration on day 0 and on week 4 (repeated injection)~② Arm2: K-MMSE 10\~19 CB-AC-02 administration on day 0 and on week 4 (repeated injection)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Stage2:~Placebo administration on day 0 and on week 4 (repeated injection)